U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335627) titled 'Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection' on Jan. 02.
Brief Summary: Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained.
The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections.
The primary objective of this st...